There has been a multi-center phase 1/2 clinical trial (NCT05252390) on the combined CDK4/6 inhibitor (NUV-868) with olaparib in advanced breast cancer which aims to reveal the superior therapeutic effect than PARP inhibitors alone. Here, PARP1 is linked to breast cancer.